
CONGRATULATIONS! BIOTECH COMPANY METSERA (MTSR) BUYOUT BY PFIZER (PFE) BECOMES 217TH ARORA PORTFOLIO BUYOUT
By Nigam Arora Editor’s note: This post was published yesterday in The Arora Report paid feeds. 217th Buyout Novo Nordisk (NVO) and Pfizer (PFE) have been in a bidding war over biotech Metsera (MTSR). Pfizer prevailed, making Metsera the 217th Arora portfolio company to be bought out. Late Friday evening, MTSR stock traded as high as $89 on expectations that Novo Nordisk would raise its bid. When Novo Nordisk did not raise its bid, MTSR stock fell. The Deal The value of Pfizer’s offer is $86.25 per share. The offer is for $65.60 cash and up $20.65 contingent value rights (CVR) per






